NC Biotechs: Overcoming Resistance To Developing Antibiotic Resistant Therapies

Antibiotic resistance is a growing global crisis with tremendous public health implications. Whenever new antibiotics are introduced, resistance to them will invariably develop, so there is a constant battle to come up with new and better treatments to attack the superbugs that have successfully adapted to older therapies.

As big pharma has largely moved away from antibiotic development over the past couple of decades, small and midsized biopharmaceutical companies have stepped into the breach. These companies face significant challenges. If they fail, the threats to modern medicine are real and potentially severe. But there is hope on the horizon, and optimism that new treatments are on the way.